Patents by Inventor Yonglong CAI

Yonglong CAI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250009871
    Abstract: Disclosed are an application of a coronavirus SARS-CoV-2 vaccine polypeptide, a polypeptide composition and a nanoemulsion preparation thereof in the prevention of coronavirus SARS-CoV-2 wild and mutant strain infections. Specifically, provided is a coronavirus SARS-CoV-2 vaccine polypeptide having an amino acid sequence derived from an S protein of SARS-CoV-2 wild and mutant strains, the vaccine polypeptide can enable the body to generate high-level and durable humoral immune responses against SARS-CoV-2 and to produce high titers of RBD-binding antibodies and neutralizing antibodies that block the binding of RBD to ACE2. The vaccine polypeptide can be used to prevent infections of SARS-CoV-2 wild strain and B.1.1.7, B.1.351, B.1.617, B.1.1.529 and other mutant strains.
    Type: Application
    Filed: May 30, 2022
    Publication date: January 9, 2025
    Inventors: Likun GONG, Jin REN, Wei HUANG, Yong GAN, Yongtang ZHENG, Jianhua SUN, Xinxin ZHANG, Yiru LONG, Qiuping QIN, Tingting LIU, Feng TANG, Pan YU, Yunqiu MIAO, Yonglong CAI, Mian QIN, Tianzhang SONG